CN101787393A - 骨桥蛋白三个转录本快速诊断试剂盒及其使用方法 - Google Patents
骨桥蛋白三个转录本快速诊断试剂盒及其使用方法 Download PDFInfo
- Publication number
- CN101787393A CN101787393A CN200910200727A CN200910200727A CN101787393A CN 101787393 A CN101787393 A CN 101787393A CN 200910200727 A CN200910200727 A CN 200910200727A CN 200910200727 A CN200910200727 A CN 200910200727A CN 101787393 A CN101787393 A CN 101787393A
- Authority
- CN
- China
- Prior art keywords
- opn
- primer
- transcript
- transcripts
- fast quantification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 15
- 108010081689 Osteopontin Proteins 0.000 title abstract description 57
- 102000004264 Osteopontin Human genes 0.000 title abstract description 56
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 239000003153 chemical reaction reagent Substances 0.000 claims description 20
- 230000014509 gene expression Effects 0.000 claims description 16
- 238000003753 real-time PCR Methods 0.000 claims description 16
- 238000012360 testing method Methods 0.000 claims description 16
- 238000011002 quantification Methods 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 239000002299 complementary DNA Substances 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 238000010839 reverse transcription Methods 0.000 claims description 9
- 102000007469 Actins Human genes 0.000 claims description 6
- 108010085238 Actins Proteins 0.000 claims description 6
- 239000000975 dye Substances 0.000 claims description 6
- 230000002103 transcriptional effect Effects 0.000 claims description 6
- 102100034343 Integrase Human genes 0.000 claims description 5
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 5
- 239000013642 negative control Substances 0.000 claims description 5
- 238000002123 RNA extraction Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000004087 circulation Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 238000007405 data analysis Methods 0.000 claims description 2
- 238000011897 real-time detection Methods 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 18
- 238000001514 detection method Methods 0.000 abstract description 14
- 238000002360 preparation method Methods 0.000 abstract description 7
- 238000011160 research Methods 0.000 abstract description 5
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 210000005259 peripheral blood Anatomy 0.000 abstract description 4
- 239000011886 peripheral blood Substances 0.000 abstract description 4
- 238000011282 treatment Methods 0.000 abstract description 4
- 230000028327 secretion Effects 0.000 abstract description 2
- 238000013139 quantization Methods 0.000 abstract 2
- 239000004615 ingredient Substances 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000003321 amplification Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000034196 cell chemotaxis Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000003375 selectivity assay Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
opn | ACCESSION | mRNA | 分子量(kDa) |
版本1(a) | NM_001040058 | 1641bp | 35 |
版本3(c) | NM_001040060 | 1560bp | 32 |
版本2(b) | NM_000582 | 1616bp | 33 |
试剂 | 体积(μl) |
Sybr premix ex Tag | 10 |
正向引物+反向引物 | 0.25+0.25 |
cDNA | 1.0 |
ddH2O | 8.5 |
总体积 | 20 |
试剂 | 每管加入量 |
5×RT buffer | 4μl |
10mM dNTPs | 2μl |
RNasin | 0.5μl |
M-MLV-RTase | 1μl |
RNA-free H2O | 3.5μl |
目的基因 | Ct(三复孔) | Ct平均值 | 标准曲线回归公式(y:每ul模板溶液中的模板拷贝数的Lg值;X:Ct值) | y值,即Lg(copy/ul) | Z值:每ul模板溶液中的模板拷贝数(copy/ul) | 每ul样本cDNA原液中的copy数=Z*待测模板稀释倍数(此处为4.4) |
ACTIN | 18.5 | 18.4 | y=-0.241x+12.95 | 8.52 | 3.33E+08 | 1.47E+09 |
18.26 | ||||||
18.34 | ||||||
OPN-A | 21.63 | 21.4 | y=-0.282x+11.98 | 5.96 | 9.05E+05 | 3.98E+06 |
21.43 | ||||||
21.01 | ||||||
OPN-B | 22.12 | 22.2 | y=-0.319x+13.53 | 6.44 | 2.73E+06 | 1.20E+07 |
22.15 | ||||||
22.45 | ||||||
OPN-C | 27.06 | 27.1 | y=-0.313x+13.22 | 4.75 | 5.59E+04 | 2.46E+05 |
目的基因 | Ct(三复孔) | Ct平均值 | 标准曲线回归公式(y:每ul模板溶液中的模板拷贝数的Lg值;X:Ct值) | y值,即Lg(copy/ul) | Z值:每ul模板溶液中的模板拷贝数(copy/ul) | 每ul样本cDNA原液中的copy数=Z*待测模板稀释倍数(此处为4.4) |
26.87 | ||||||
27.27 |
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200910200727 CN101787393B (zh) | 2009-12-24 | 2009-12-24 | 骨桥蛋白三个转录本快速诊断试剂盒及其使用方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200910200727 CN101787393B (zh) | 2009-12-24 | 2009-12-24 | 骨桥蛋白三个转录本快速诊断试剂盒及其使用方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101787393A true CN101787393A (zh) | 2010-07-28 |
CN101787393B CN101787393B (zh) | 2013-01-09 |
Family
ID=42530771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200910200727 Expired - Fee Related CN101787393B (zh) | 2009-12-24 | 2009-12-24 | 骨桥蛋白三个转录本快速诊断试剂盒及其使用方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101787393B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104165913A (zh) * | 2014-05-19 | 2014-11-26 | 上海大学 | 检测骨桥蛋白的电化学传感器及其构建方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2632327A1 (en) * | 2005-12-22 | 2007-06-28 | F. Hoffmann-La Roche Ag | Use of a marker combination comprising osteopontin and carcinoembryonic antigen in the assessment of colorectal cancer |
CN101210037A (zh) * | 2006-12-26 | 2008-07-02 | 上海吉凯基因化学技术有限公司 | 一种针对人opn基因用于肿瘤基因治疗的短的干扰核糖核酸 |
-
2009
- 2009-12-24 CN CN 200910200727 patent/CN101787393B/zh not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104165913A (zh) * | 2014-05-19 | 2014-11-26 | 上海大学 | 检测骨桥蛋白的电化学传感器及其构建方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101787393B (zh) | 2013-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103146688B (zh) | 长链非编码rna作为疾病诊断血液分子标志物的应用 | |
CN102985558B (zh) | 用于肝细胞癌症的微rna表达谱分析的组合物和方法 | |
Nguyen et al. | A panel of TMPRSS2: ERG fusion transcript markers for urine-based prostate cancer detection with high specificity and sensitivity | |
Onder et al. | Classic architecture with multicentricity and local recurrence, and absence of TERT promoter mutations are correlates of BRAF V600E harboring pediatric papillary thyroid carcinomas | |
Sakurada et al. | Detection of dermcidin for sweat identification by real-time RT-PCR and ELISA | |
CN109182521B (zh) | circRNA作为甲状腺乳头状癌标志物的应用 | |
AU2020100457A4 (en) | USE OF circRNA IN PREPARATION OF DIAGNOSTIC KIT FOR HEPATOCELLULAR CARCINOMA AND KIT USING circRNA | |
CN101711287A (zh) | 确定肝细胞癌亚型和检测肝癌干细胞的方法 | |
US20110256547A1 (en) | MicroRNAa (miRNA) AS BIOMARKERS FOR DIAGNOSING DIFFERENT GRADES OF GLIOMAS AND PATHWAYS OF GLIOMA PROGRESSION | |
CN104168915A (zh) | 治疗癌症的方法 | |
CN105838818B (zh) | Nfic基因在制备垂体瘤诊治产品中的应用 | |
CN102892898A (zh) | 用于肝细胞癌诊断的含微rna生物标记的诊断试剂盒和方法 | |
CN106701900A (zh) | 长链非编码rna herc2p3基因及其在胃癌中的用途 | |
CN108753969A (zh) | 长链非编码rna在肝细胞癌诊疗中的应用 | |
KR20190077309A (ko) | 식도암 진단 및 치료 방법 | |
CN106967719B (zh) | 一种长链非编码rna作为前列腺癌分子标志物的应用 | |
CN109576366B (zh) | lnc-TALC作为分子标志物在评估胶质母细胞瘤TMZ化疗疗效和预后中的用途 | |
CN110229910A (zh) | Myd88基因l265p突变检测试剂盒及检测方法 | |
Bai et al. | Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine | |
Trombetta et al. | Liquid biopsy and NSCLC | |
CN105400885A (zh) | Tff2基因作为颅内动脉瘤诊治标志物的用途 | |
CN101787393B (zh) | 骨桥蛋白三个转录本快速诊断试剂盒及其使用方法 | |
CN106755309A (zh) | 分子标记物在制备胰腺癌预后评估产品中的应用 | |
CN102109525B (zh) | 一种检测血液中游离乳腺癌细胞标志物的试剂盒 | |
CN102409090A (zh) | 凋亡抑制蛋白Survivin基因核酸检测探针、引物、试剂盒及其检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20100728 Assignee: SHANGHAI JI KAI GENE TECHNOLOGY Co.,Ltd. Assignor: SHANGHAI GENECHEM Co.,Ltd. Contract record no.: 2014310000193 Denomination of invention: Kit for rapidly diagnosing three transcripts of osteopontin (OPN) and use method thereof Granted publication date: 20130109 License type: Exclusive License Record date: 20141223 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 200233, room 680, 619-21 Guiping Road, Shanghai, Xuhui District Patentee after: Shanghai Jikai gene Medical Technology Co.,Ltd. Address before: 200233, room 680, 619-21 Guiping Road, Shanghai, Xuhui District Patentee before: SHANGHAI GENECHEM Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130109 |